Discover the benefits of a new migraine-preventing drug

Get to pharmacies the definitive cure to end migraines. Fool (rimegepant) is the first drug to prevent migraine attacks. Commercial use Pfizerthis is a treatment eliminates pain and the most unpleasant symptoms two hours after consumption. With this progress, the days of this neurological disease appear to be numbered.

Fool was approved by the European Commission in April 2022. In the state, the Interministerial Commission on Drug Prices approved funding for this drug which has been available since January last year. Requires medical prescriptionbut government funding does not cover all patients.

José Chavez, medical director of Pfizer Spain, explained: keys to access Vidura: “The funded indication is prevention with some restrictions: patients who suffer from 8 to 14 migraine attacks per monthwho at least passed three previous treatments without an adequate response for three months and received recipe from a specialist”

However, patients who do not meet these requirements can purchase it from pharmacies. at market price: 29 euros per tablet, and always according to the recipe. dose recommended for emergency therapy – one per daywhile Recommended prevention is one of two.

For advantages According to Vydura, the drug brings countless benefits to the patient. Most noticeable According to Pfizer, they are as follows:

• Since it is a prophylactic drug, This helps eradicate the disease from the very beginning.

• In two hours or lessthe symptoms of this disease can be reduced.
• Relieves painreduces vasodilation of the neuropeptide CGRP and reduces neurogenic inflammation.

• The drug is administered orallyunlike other tablets.

• Their side effects they are very scarce.

• 40% of patients reduce by 50% or more migraine days per month.

About migraine

This is a neurological disease This affects 12% of the state’s population.. That is, about four million people suffer from this disease. Of all of them, 80% womenincluded age range between 20 and 40 years.

According to research conducted WHOin all world There is more than 1 billion people affected. Similarly, migraine is one of the ten most disabling pathologies because 90% of patients are unable to perform daily activities during a crisis.